跳至主要内容
临床试验/NL-OMON30655
NL-OMON30655已完成不适用

Differential effect of adalumimab versus etanercept on apoptosis in the psoriatic skin - Adalumimab versus etanercept; apoptosis in the psoriatic skin

niversitair Medisch Centrum Groningen0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Man and woman older than 18 year en younger than 75 year
  • 2. Diagnosis of Psoriatic arthritis with involvement of the peripheral joints
  • 3. Failure on etanercept therapy as measured by PASI and DAS
  • 4. Indication for treatment with etanercept according to the LABAG guidelines
  • 5. Active disease despite treatment with methotrexate and etanercept, MTX >_ 15 mg/wk in a stable dosis during 3 months; still active skin lesions despite MTX and etanercept treatment
  • 5. Corticosteroids (max 10 mg/day) en NSAID*s stable dose.
  • 6. Signed informed consent.

排除标准

  • 1. Rheumatoid arthritis and/or other autoimmune diseases
  • 2. Pregnancy / breastfeeding.
  • 3. TBC/ hepatitis b or c or other chronic infections.
  • 4. Contraindications for TNF-alpha like a malignancy or a chronic demyelinating disease.
  • 5. No participation in another study.
  • 6. No PUVA or vitamine D treatment during 1 month before and during the study.

研究者

相似试验